Yahoo Web Search

Search results

1. • • Von Willebrand disease cannot be cured, but it can be treated. Early diagnosis is important, and with the right treatment plan, even people with type 3 VWD can be helped to live active lives.
     www.nhlbi.nih.gov › files › docs

     IN BRIEF YOUR GUIDE TO von Willebrand Disease - NHLBI, NIH

2. People also ask

   What is von Willebrand disease (vWD)?

   • Von Willebrand disease (VWD) is the most common inherited bleeding disorder, yet diagnosis and management remain challenging. Development and use of bleeding assessment tools allows for improved stratification of which patients may require further assessment and which patients are most likely to require treatment of their VWD.

   Advances in the diagnosis and treatment of Von Willebrand disease

   www.ncbi.nlm.nih.gov/pmc/articles/PMC5709787/

   See all results for this question

   Does the father have von Willebrand disease?

   • There is a possible family history of von Willebrand disease (VWD) in the father, but he does not live with the family.

   New advances in the diagnosis of von Willebrand disease - PMC

   www.ncbi.nlm.nih.gov/pmc/articles/PMC6913428/

   See all results for this question

   Do joint bleeds affect quality of life in von Willebrand disease patients?

   • Joint bleeds in von Willebrand disease patients have significant impact on quality of life and joint integrity: a cross-sectional study. Haemophilia. 2015;21(3):e185-e192. [ PubMed] [ Google Scholar] 50. Govorov I, Ekelund L, Chaireti R, et al.. Heavy menstrual bleeding and health-associated quality of life in women with von Willebrand’s disease.

   Advances in the diagnosis and treatment of Von Willebrand disease

   www.ncbi.nlm.nih.gov/pmc/articles/PMC5709787/

   See all results for this question

3. ashpublications.org › blood › articlevon Willebrand disease: what does the future hold? | Blood ...

   ashpublications.org › blood › article

   • Cached

   Apr 29, 2021 · In conclusion, yes, there are some efficient treatments for VWD, but, no, this does not mean that we should stop trying to improve these treatments with the goals of reaching superior efficacy, improving quality of life of the patients, and finally, curing the disease.

   • Author: Cécile V Denis, Sophie Susen, Peter J Lenting

   • Publish Year: 2021

4. www.ncbi.nlm.nih.gov › pmc › articlesVon Willebrand factor and cancer: Another piece of the puzzle

   www.ncbi.nlm.nih.gov › pmc › articles

   Jul 29, 2022 · The data presented by Dhami and colleagues bring yet another piece to the puzzle, linking VWF to malignant diseases, this time in metastatic breast cancer. Animal studies confirming such results could extend and strengthen even further the relevance of this study.

   • DOI: 10.1111/jth.15810

   • Published: 2022/10

5. www.ncbi.nlm.nih.gov › pmc › articlesNew advances in the diagnosis of von Willebrand disease - PMC

   www.ncbi.nlm.nih.gov › pmc › articles

   Dec 6, 2019 · von Willebrand disease (VWD) is the most common autosomal inherited bleeding disorder, with an estimated prevalence of 1 in 1000 individuals. VWD is classified into quantitative and qualitative forms. Diagnosis of VWD is complex and requires (1) a personal history of bleeding symptoms, (2) family history of bleeding or VWD, and (3) confirmatory ...

   • Author: Ruchika Sharma, Sandra L. Haberichter
   • DOI: 10.1182/hematology.2019000064

   • Publish Year: 2019
   • Published: 2019/12/12

6. www.ncbi.nlm.nih.gov › pmc › articlesAdvances in the diagnosis and treatment of Von Willebrand disease

   www.ncbi.nlm.nih.gov › pmc › articles

   Nov 11, 2017 · Plasma-derived VWF has been available for decades and is both safe and effective in treating bleeds in VWD. Most currently available concentrates contain both VWF and FVIII, although the ratio varies by product. Humate-P has a VWF:FVIII ratio of approximately 2.4:1, whereas Wilate has a ratio of approximately 1:1.

   • Author: Ruchika Sharma, Ruchika Sharma, Veronica H. Flood, Veronica H. Flood, Veronica H. Flood
   • DOI: 10.1182/blood-2017-05-782029

   • Publish Year: 2017
   • Publication: Blood. 2017 Nov 30; 130(22): 2386-2391.

7. www.octapharma.com › news › innovation-and-scienceWIL-31: Expanding treatment options for VWD

   www.octapharma.com › news › innovation-and-science

   • Cached

   Launched by Octapharma in 2020 and completed in November 2022, WIL-31 was a prospective, non-controlled, international, multi-centre phase III trial that investigated the efficacy and safety of Octapharma's von Willebrand factor prophylaxis over 12 months in people aged six and older with severe VWD of any type.

8. pubmed.ncbi.nlm.nih.gov › 33571850The role of von Willebrand factor in breast cancer metastasis

   pubmed.ncbi.nlm.nih.gov › 33571850

   Published by Elsevier Inc. All rights reserved. Publication types. Review. Breast cancer is the most common female cancer globally, with approximately 12% of patients eventually developing metastatic disease. Critically, limited effective treatment options exist for metastatic breast cancer.

9. cancer.osu.edu › for-patients-and-caregivers › learnVon Willebrand Disease Types & Symptoms | OSUCCC – James

   cancer.osu.edu › for-patients-and-caregivers › learn

   • Cached

   There are three main classifications for von Willebrand disease: Type 1 is the mildest and most diagnosed form of VWD (about three out of four people with VWD have Type 1). These patients have low levels of the von Willebrand factor and may also have low factor VIII levels. Type 2 is caused by different genetic changes, or mutations, from Type 1.